Compare ProShares Bitcoin ETF (BITO) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Bitcoin ETF vs Bristol-Myers Squibb Co — how do they compare? ProShares Bitcoin ETF trades at $8.61, while Bristol-Myers Squibb Co trades at $63.69 (market cap $132.45B). The key difference: Bristol-Myers Squibb Co pays a 3.89% dividend while ProShares Bitcoin ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BITO | BMY | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $22.27 | $65.89 |
52-Week Low | $7.98 | $42.60 |
Market Cap | — | $132.45B |
Enterprise Value | — | $166.44B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITO trades at $8.79, up 1.03% with a bullish technical signal from moving averages. The ETF maintains a consistent dividend distribution pattern with recent $0.01 payouts. Technical indicators show neutral oscillators but overall positive momentum, with support and resistance clustered around $9. The fund's performance reflects ongoing investor interest in Bitcoin exposure vehicles despite market volatility.
BITO faces structural challenges with higher fees impacting long-term returns compared to spot Bitcoin ETFs. Recent analyst coverage highlights tactical utility but questions buy-and-hold suitability. The fund's correlation breakdown with high-beta equities and persistent crypto market headwinds present significant risk factors for investors seeking sustained growth.
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Bitcoin ETF
BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
